我们旨在阐明导致阿尔茨海默病 (AD) 的早期病因到后期缺陷的基因通路，这种疾病很常见且致命，且尚无有效的疾病改良药物 ...

Research Objective The research proposed here will support the development of NGL-101, a cell therapy for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).

Welcome to the frequently asked questions (FAQs) page of the California Institute for Regenerative Medicine (CIRM). Here, you’ll find answers to the most common questions you may have on CIRM. CIRM, ...

Jonathan Thomas, PhD, JD, is President and CEO of the California Institute for Regenerative Medicine (CIRM). Thomas was previously the Chair of the CIRM governing Board from June 2011 to March 2023.

Through its strategic funding of clinical trials, CIRM helps advance innovative stem cell and gene therapy discoveries toward future treatments for patients. CIRM funds clinical trials across a broad ...

The CIRM iPSC Repository is a collection of induced pluripotent stem cell (iPSC) lines produced from tissue samples obtained from thousands of individuals by researchers in California through funding ...

The California Institute for Regenerative Medicine (CIRM) was established in 2004 when 59 percent of California voters passed Proposition 71, also known as the California Stem Cell Research and Cures ...

CIRM is dedicated to bringing regenerative medicine treatments to patients who need them. This commitment begins with access to information. This page provides resources to learn more about ...

Currently, CIRM is not accepting new applications for any existing Clinical (CLIN), Translational (TRAN), Education (EDUC), or Infrastructure (INFR) opportunities. However, CIRM will accept ...

Anne-Marrie Duliege, MD, is a Senior Executive and Chief Medical Officer with 30 years of experience guiding biopharmaceutical companies through development and commercial stages. Dr. Duliege is ...

Up to 12,000 Americans suffer a spinal cord injury (SCI) each year. This condition leads to a high level of permanent disability and decreased life expectancy. Currently, there are no approved ...